GlassScriptPhysician profile
Sarah E Anderson
NPI 1639723893
$3,774.20
in general payments reported to CMS, 2019-2025
30 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $258 · 2023: $204 · 2024: $2,604 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809 · Travel and Lodging: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.65 |
| Travel and Lodging | $557.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $946.11 | 2024 | Axonics |
| Sumitomo Pharma America, INC. | $636.98 | 2024-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $247.24 | 2022-2024 | Xtandi |
| Accord Healthcare, INC. | $213.05 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $162.15 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $141.54 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.99 | 2021-2022 | |
| Endo USA, INC. | $136.67 | 2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $128.66 | 2024-2025 | |
| Janssen Biotech, INC. | $116.60 | 2025 | Carvykti, Rybrevant |
| Urogen Pharma, INC. | $94.54 | 2024 | |
| Eisai INC. | $94.26 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $75.07 | 2023-2024 | Bard Urinary Drainage Bag |
| Pfizer INC. | $73.36 | 2024-2025 | |
| Teleflex LLC | $69.11 | 2021-2025 | Barrigel, Urolift |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $66.53 | 2022 | |
| Abbvie INC. | $64.69 | 2024 | |
| Blue Earth Diagnostics | $58.64 | 2023-2024 | |
| Novo Nordisk INC | $56.74 | 2024-2025 | Rivfloza |
| Novartis Pharmaceuticals Corporation | $47.03 | 2024-2025 | |
| Ambu INC. | $40.18 | 2024 | |
| Antares Pharma, INC. | $31.72 | 2024-2025 | Xyosted |
| Clarus Therapeutics INC. | $22.04 | 2021 | |
| Coloplast Corp | $20.58 | 2025 | |
| Immunitybio, INC. | $19.26 | 2025 | |
| Innovation Technologies INC | $14.87 | 2024 | Irrisept |
| Supernus Pharmaceuticals, INC. | $14.62 | 2022 | |
| Endo Pharmaceuticals INC. | $14.49 | 2024 | Aveed, Xiaflex |
| Myriad Genetic Laboratories, INC. | $13.95 | 2023 | Prolaris |
| Lundbeck LLC | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.